# A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948)

> **NCT00779129** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 70 (actual)

## Conditions studied

- Breast Neoplasm

## Interventions

- **DRUG:** Pegylated Lyposomal Doxorubicin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT00779129
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03
- **Primary completion:** 2007-08
- **Final completion:** 2007-08
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2015-09-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00779129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00779129, "A Study to Evaluate Safety and Efficacy of Caelyx in Combination With Cyclophosphamide in the Treatment of Metastatic Breast Cancer (P02948)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00779129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*